PFE Pfizer Inc

$PFE $NVAX IDWeek 2026 runs Oct 21–24, and Pfizer is presenting 57 abstracts there, including 12 oral presentations with clinical milestones for its next-gen pediatric pneumococcal vaccine and registrational Lyme vaccine. Positive readouts would be a genuine catalyst. Any surprisre announcements will move it to the 35

$PFE I see some celebrating on the board today for those who have held for an extended period of time. This is only the beginning.

$PFE If we could just get any good news besides being in the same sector as Lilly we would rip higher

$PFE $SPY Investors are making major shifts, moving out of tech, finance, telecom, and consumer goods and into healthcare and defense at this point in time. 🤣 People are worried about global instability, trade wars, potential future viral outbreaks, inflation, and recession

$PFE time to get back to 60 as I've been averaging now for the last few years. I have too much money tied up here.

$PFE I literally was rubbing my eyes if I was seeing the right numbers here.. wow. Good to see 30s... just wow.

$PFE NOV06 30C · still actionable Zone: $29.23 to $29.65 Invalidation: close under $28.85 Objectives: $31.25, then $33 The math: up 6.1% to the first objective and 12.1% to the second, against 2.0% risk on the invalidation, better than 6 to 1 to the second Dear friend, picture a big steady name that has climbed a quiet staircase from the high 27s to right under its yearly high at $29.88 and is now pausing instead of falling apart. That is why this swing into the November 3 earnings report interests me. A push through that high would tell us buyers still want it with the report date known, and the room above stays open until the low 31s. If it loses $28.85 on a close, the staircase story is broken and I step aside. P.S. Watch $29.88 first. It is the yearly high, and everything in this plan starts with how price acts around that one number.

$PFE re-iterating the same , perfect time to send it to 35 with a news given market conditions very much favorable

$PFE given the market condition , $LLY $PFE showing the strength is commandable . perfect time to drop the news and move it to 35 this week

$PFE I felt dumb last year when I loaded the boat during the tariff crash and it kept dipping...but now I'm over +25% and in addition the dividends have been juicy💪 Holding ♾️, probably

DEFEATING THE BEAST SYSTEM BIOWEAPONS The beast system is going to be implemented whether we like it or not. We are not going to vote our way out of it. We may be able to vote our way out of mass migration but the plan is to inject every American with mRNA vaccines from $PFE $BNTX $MRNA and now $MRK and $GSK. The good news is ... it isn't hard to defeat this system. All these bioweapons run on lipid nano particles aka poly ethylene glycol. These systems disassemble with EDTA which should be taken with a charcoal binder. So if you are forced to take one of these to keep your job or enroll your child in school take them an hour before having to take any mRNA injection. And since so many people will be injected and they are designed to shed it would be wise to detox this way monthly. And since they are now using them on pets and farm animals it would be good to detox them also. Share on X and all your social media channels.

$PFE NOV06 30C · still actionable Zone: $29.23 to $29.65 Invalidation: close under $28.55 Objectives: $31.25, then $33 The math: up 6.1% to the first objective and 12.1% to the second, against 3.0% risk on the invalidation, about 4 to 1 to the second Dear friend, picture a big old ship that spent a long time turning and is finally pointing the way it wants to go. Pfizer eased to $29.44 today after touching $29.88 last week, its highest price in a year, and buyers held the low at $29.25, which tells you the recent strength is still being defended. What that means is simple: this is a swing setup into earnings on November 3, and a push back over that yearly high opens room toward the objectives above, while a close under $28.55 would say the breakout day floor failed and you step aside. P.S. Watch $29.88 first. It is the yearly high from last week, and a close over it would show buyers pushing again, not just defending.

$PFE some of you know me from years back being on here. Just letting you know I am pretty much fully out at 30 per share. It has been a wild ride the last 4 years in this stock but came away selling at a profit and collecting an average 7 percent yield along the way. It seemed bleak at times but I stuck to my thesis that this was undervalued. Now I feel like it can power higher but moving on. Make sure to dollar cost average when a stock you believe in falls. There were some great guy opportunities at 22 per share many times over the last few years.

$PFE $29.5 CC getting assigned tomorrow held through the COVID highs, spend a year averaging down at ever downturn. Happy to end up making a ~20% profit here on top of the 6 years of dividends

$PFE NOV06 31C · still actionable Zone: $29.37 to $29.79 Invalidation: close under $28.55 Objectives: $31.40, then $33.10 The math: up 6.2% to the first objective and 11.9% to the second, against 3.5% risk on the invalidation, better than 3 to 1 to the second Think of this swing setup like a quiet neighbor who keeps paying his bills on time while everyone watches the louder houses on the street. Pfizer closed Friday at $29.58, up 4.6 percent in five sessions, and buyers held the $29.42 low on both Thursday and Friday, which tells you demand showed up right under price, not far below it. Earnings on November 3 give this move a clear date to work toward, and a close over the $29.88 high would mean buyers are willing to pay a new yearly high for that report. If price closes under $28.55 the quiet strength story is wrong and you step aside, plain and simple. P.S. Watch $29.88 on Monday. It is the highest price buyers have paid in a year, and clearing it changes the conversation from recovery to breakout.

$PFE Rotation in to Biotech has started ahead of a Democrat sweep in November. $PFE on track to be over $50 by Spring 2027.

$PFE My lot of 1,000 shares at $24.50 looking real good -- seagen pipline + AI will be accelerant.

$PFE still on the road to $30 and beyond WINS FDA APPROVAL FOR TUKYSA + TRASTUZUMAB/PERTUZUMAB AS MAINTENANCE TREATMENT IN HER2+ METASTATIC BREAST CANCER

$PFE Now would be a perfect time for some good news, Albert. The market is begging for a reason to launch us higher but you've got to give them something, anything good will do. Thanks

$PFE The fact that Moderna could soon be worth as much as Pfizer is completely insane